{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:33:55Z","timestamp":1790771635938,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Bethune\u00b7Cancer Radiotherapy Translational Medicine Research Fund","award":["flzh202107"],"award-info":[{"award-number":["flzh202107"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972796 and 82272845"],"award-info":[{"award-number":["81972796 and 82272845"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Research and Development Program of Shandong","award":["2021SFGC0501"],"award-info":[{"award-number":["2021SFGC0501"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The CREST study showed that the addition of thoracic radiotherapy (TRT) could improve the survival rate in patients with extensive stage small cell lung cancer (ES-SCLC), but whether TRT can bring survival benefit in the era of immunotherapy remains controversial. This study aimed to explore the efficacy and safety of adding TRT to the combination of PD-L1 inhibitors and chemotherapy.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The patients who received durvalumab or atezolizumab combined with chemotherapy as the first-line treatment of ES-SCLC from January 2019 to December 2021 were enrolled. They were divided into two groups, based on whether they received TRT or not. Propensity score matching (PSM) with a 1:1 ratio was performed. The primary endpoints were progression-free survival (PFS), overall survival (OS) and safety.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 211 patients with ES-SCLC were enrolled, of whom 70 (33.2%) patients received standard therapy plus TRT as first-line treatment, and 141 (66.8%) patients in the control group received PD-L1 inhibitors plus chemotherapy. After PSM, a total of 57 pairs of patients were enrolled in the analysis. In all patients, the median PFS (mPFS) in the TRT and non-TRT group was 9.5 and 7.2\u00a0months, respectively, with HR\u2009=\u20090.59 (95%CI 0.39\u20130.88, <jats:italic>p<\/jats:italic>\u2009=\u20090.009). The median OS (mOS) in the TRT group was also significantly longer than that in the non-TRT group (24.1\u00a0months vs. 18.5\u00a0months, HR\u2009=\u20090.53, 95%CI 0.31\u20130.89, <jats:italic>p<\/jats:italic>\u2009=\u20090.016). Multivariable analysis showed that baseline liver metastasis and the number of metastases\u2009\u2265\u20093 were independent prognostic factors for OS. Addition of TRT increased the incidence of treatment-related pneumonia (<jats:italic>p<\/jats:italic>\u2009=\u20090.018), most of which were grade 1\u20132.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Addition of TRT to durvalumab or atezolizumab plus chemotherapy significantly improves survival in ES-SCLC. Although it may leads to increased incidence of treatment-related pneumonia, a majority of the cases can be relieved after symptomatic treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-023-02308-2","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T22:01:50Z","timestamp":1688508110000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer"],"prefix":"10.1186","volume":"18","author":[{"given":"Jianfeng","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lemeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningbo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjiao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"2308_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","volume":"7","author":"CM Rudin","year":"2021","unstructured":"Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:3.","journal-title":"Nat Rev Dis Primers"},{"key":"2308_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M, Keijser A, Faivre-Finn C, Senan S. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015;385:36\u201342.","journal-title":"Lancet"},{"key":"2308_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.prro.2020.02.009","volume":"10","author":"CB Simone 2nd","year":"2020","unstructured":"Simone CB 2nd, Bogart JA, Cabrera AR, Daly ME, DeNunzio NJ, Detterbeck F, Faivre-Finn C, Gatschet N, Gore E, Jabbour SK, Kruser TJ, Schneider BJ, Slotman B, Turrisi A, Wu AJ, Zeng J, Rosenzweig KE. Radiation therapy for small cell lung cancer: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2020;10:158\u201373.","journal-title":"Pract Radiat Oncol"},{"key":"2308_CR4","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220\u20139.","journal-title":"N Engl J Med"},{"key":"2308_CR5","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, \u00d6zg\u00fcro\u011flu M, Ji JH, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Kazarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Shire N, Jiang H, Goldman JW. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929\u201339.","journal-title":"Lancet"},{"key":"2308_CR6","doi-asserted-by":"publisher","first-page":"153303382110399","DOI":"10.1177\/15330338211039948","volume":"20","author":"H Li","year":"2021","unstructured":"Li H, Yu H, Lan S, Zhao D, Liu Y, Cheng Y. Aberrant alteration of circulating lymphocyte subsets in small cell lung cancer patients treated with radiotherapy. Technol Cancer Res Treat. 2021;20:15330338211039948.","journal-title":"Technol Cancer Res Treat"},{"key":"2308_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627197","volume":"12","author":"B Li","year":"2021","unstructured":"Li B, Jiang C, Pang L, Zou B, Ding M, Sun X, Yu J, Wang L. Toxicity profile of combining PD-1\/PD-L1 inhibitors and thoracic radiotherapy in non-small cell lung cancer: a systematic review. Front Immunol. 2021;12: 627197.","journal-title":"Front Immunol"},{"key":"2308_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215719","volume":"541","author":"Y Tian","year":"2022","unstructured":"Tian Y, Ma J, Jing X, Zhai X, Li Y, Guo Z, Yu J, Zhu H. Radiation therapy for extensive-stage small-cell lung cancer in the era of immunotherapy. Cancer Lett. 2022;541: 215719.","journal-title":"Cancer Lett"},{"issue":"21","key":"2308_CR9","doi-asserted-by":"publisher","first-page":"12728","DOI":"10.3390\/ijms232112728","volume":"23","author":"G Guaitoli","year":"2022","unstructured":"Guaitoli G, Neri G, Cabitza E, Natalizio S, Mastrodomenico L, Talerico S, Trudu L, Lauro C, Chiavelli C, Baschieri MC, Bruni A, Dominici M, Bertolini F. Dissecting immunotherapy strategies for small cell lung cancer: antibodies, ionizing radiation and CAR-T. Int J Mol Sci. 2022;23(21):12728.","journal-title":"Int J Mol Sci"},{"key":"2308_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.chest.2019.03.033","volume":"156","author":"AN Hanania","year":"2019","unstructured":"Hanania AN, Mainwaring W, Ghebre YT, Hanania NA, Ludwig M. Radiation-induced lung injury: assessment and management. Chest. 2019;156:150\u201362.","journal-title":"Chest"},{"key":"2308_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.918787","volume":"13","author":"X Lu","year":"2022","unstructured":"Lu X, Wang J, Zhang T, Zhou Z, Deng L, Wang X, Wang W, Liu W, Tang W, Wang Z, Wang J, Jiang W, Bi N, Wang L. Comprehensive pneumonitis profile of thoracic radiotherapy followed by immune checkpoint inhibitor and risk factors for radiation recall pneumonitis in lung cancer. Front Immunol. 2022;13: 918787.","journal-title":"Front Immunol"},{"key":"2308_CR12","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/cncr.29098","volume":"121","author":"LA Byers","year":"2015","unstructured":"Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer. 2015;121:664\u201372.","journal-title":"Cancer"},{"key":"2308_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256\u201365.","journal-title":"J Natl Cancer Inst"},{"key":"2308_CR14","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol. 2015;1:1325\u201332.","journal-title":"JAMA Oncol"},{"key":"2308_CR15","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.ijrobp.2012.12.025","volume":"86","author":"J Zeng","year":"2013","unstructured":"Zeng J, See AP, Phallen J, Jackson CM, Belcaid Z, Ruzevick J, Durham N, Meyer C, Harris TJ, Albesiano E, Pradilla G, Ford E, Wong J, Hammers HJ, Mathios D, Tyler B, Brem H, Tran PT, Pardoll D, Drake CG, Lim M. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2308_CR16","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","volume":"3","author":"SS Park","year":"2015","unstructured":"Park SS, Dong H, Liu X, Harrington SM, Krco CJ, Grams MP, Mansfield AS, Furutani KM, Olivier KR, Kwon ED. PD-1 restrains radiotherapy-induced abscopal effect. Cancer Immunol Res. 2015;3:610\u20139.","journal-title":"Cancer Immunol Res"},{"key":"2308_CR17","doi-asserted-by":"publisher","first-page":"5514","DOI":"10.1158\/1078-0432.CCR-16-1673","volume":"23","author":"SJ Dovedi","year":"2017","unstructured":"Dovedi SJ, Cheadle EJ, Popple AL, Poon E, Morrow M, Stewart R, Yusko EC, Sanders CM, Vignali M, Emerson RO, Robins HS, Wilkinson RW, Honeychurch J, Illidge TM. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Can Res Off J Am Assoc Can Res. 2017;23:5514\u201326.","journal-title":"Clin Can Res Off J Am Assoc Can Res"},{"key":"2308_CR18","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s40425-019-0704-z","volume":"7","author":"SO Dudzinski","year":"2019","unstructured":"Dudzinski SO, Cameron BD, Wang J, Rathmell JC, Giorgio TD, Kirschner AN. Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer. J Immunother Cancer. 2019;7:218.","journal-title":"J Immunother Cancer"},{"key":"2308_CR19","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Investig. 2014;124:687\u201395.","journal-title":"J Clin Investig"},{"key":"2308_CR20","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41416-020-0956-x","volume":"123","author":"Y Philippou","year":"2020","unstructured":"Philippou Y, Sjoberg HT, Murphy E, Alyacoubi S, Jones KI, Gordon-Weeks AN, Phyu S, Parkes EE, Gillies McKenna W, Lamb AD, Gileadi U, Cerundolo V, Scheiblin DA, Lockett SJ, Wink DA, Mills IG, Hamdy FC, Muschel RJ, Bryant RJ. Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. British J Can. 2020;123:1089\u2013100.","journal-title":"British J Can"},{"key":"2308_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092572","volume":"9","author":"Y Yoshimoto","year":"2014","unstructured":"Yoshimoto Y, Suzuki Y, Mimura K, Ando K, Oike T, Sato H, Okonogi N, Maruyama T, Izawa S, Noda SE, Fujii H, Kono K, Nakano T. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS ONE. 2014;9: e92572.","journal-title":"PLoS ONE"},{"key":"2308_CR22","doi-asserted-by":"publisher","first-page":"5379","DOI":"10.1158\/1078-0432.CCR-09-0265","volume":"15","author":"MZ Dewan","year":"2009","unstructured":"Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res Off J Am Assoc Can Res. 2009;15:5379\u201388.","journal-title":"Clin Cancer Res Off J Am Assoc Can Res"},{"key":"2308_CR23","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpe\u00f1o J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, \u00d6zg\u00fcro\u011flu M. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329.","journal-title":"N Engl J Med"},{"key":"2308_CR24","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, Vicente D, Planchard D, Paz-Ares L, Vansteenkiste JF, Garassino MC, Hui R, Quantin X, Rimner A, Wu YL, \u00d6zg\u00fcro\u011flu M, Lee KH, Kato T, de Wit M, Kurata T, Reck M, Cho BC, Senan S, Naidoo J, Mann H, Newton M, Thiyagarajah P, Antonia SJ. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III Non-Small-Cell Lung Cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2022;40:1301\u201311.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"2308_CR25","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1001\/jamaoncol.2019.1478","volume":"5","author":"W Theelen","year":"2019","unstructured":"Theelen W, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts J, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P. Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT Phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1276\u201382.","journal-title":"JAMA Oncol"},{"key":"2308_CR26","first-page":"266","volume":"15","author":"JW Welsh","year":"2020","unstructured":"Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, Simon GR, Raju U, Byers L, Glisson B. Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer. J Thoracic Oncol Off Publ Int Assoc Stud Lung Can. 2020;15:266\u201373.","journal-title":"J Thoracic Oncol Off Publ Int Assoc Stud Lung Can"},{"key":"2308_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100883","volume":"7","author":"BH Diamond","year":"2022","unstructured":"Diamond BH, Verma N, Shukla UC, Park HS, Koffer PP. Consolidative thoracic radiation therapy after first-line chemotherapy and immunotherapy in extensive-stage small cell lung cancer: a multi-institutional case series. Adv Radiat Oncol. 2022;7: 100883.","journal-title":"Adv Radiat Oncol"},{"key":"2308_CR28","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ijrobp.2020.09.031","volume":"109","author":"BA Perez","year":"2021","unstructured":"Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective single-arm phase 1 and 2 study: Ipilimumab and Nivolumab with thoracic radiation therapy after platinum chemotherapy in extensive-stage small cell lung cancer. Int J Radiat Oncol Biol Phys. 2021;109:425\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2308_CR29","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D\u2019Amico TA, D\u2019Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, Hughes M. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Can Netw JNCCN. 2021;19:1441\u201364.","journal-title":"J Natl Compr Can Netw JNCCN"},{"key":"2308_CR30","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.radonc.2017.10.005","volume":"125","author":"X Li-Ming","year":"2017","unstructured":"Li-Ming X, Zhao LJ, Simone CB 2nd, Cheng C, Kang M, Wang X, Gong LL, Pang QS, Wang J, Yuan ZY, Wang P. Receipt of thoracic radiation therapy and radiotherapy dose are correlated with outcomes in a retrospective study of three hundred and six patients with extensive stage small-cell lung cancer. Radiother Oncol J European Soc Ther Radiol Oncol. 2017;125:331\u20137.","journal-title":"Radiother Oncol J European Soc Ther Radiol Oncol"},{"key":"2308_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13014-021-01773-x","volume":"16","author":"J Han","year":"2021","unstructured":"Han J, Fu C, Li B. Clinical outcomes of extensive-stage small cell lung cancer patients treated with thoracic radiotherapy at different times and fractionations. Radiation Oncol. 2021;16:47.","journal-title":"Radiation Oncol"},{"key":"2308_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3892\/etm.2015.2526","volume":"10","author":"Z Luan","year":"2015","unstructured":"Luan Z, Wang Z, Huang W, Zhang J, Dong W, Zhang W, Li B, Zhou T, Li H, Zhang Z, Wang Z, Sun H, Yi Y. Efficacy of 3D conformal thoracic radiotherapy for extensive-stage small-cell lung cancer: a retrospective study. Exp Ther Med. 2015;10:671\u20138.","journal-title":"Exp Ther Med"},{"key":"2308_CR33","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2015.2526","author":"S Cozzi","year":"2023","unstructured":"Cozzi S, Bruni A, Ruggieri MP, Borghetti P, Scotti V, Franceschini D, Fiore M, Taraborrelli M, Salvi F, Galaverni M, Savoldi L, Braglia L, Botti A, Finocchi Ghersi S, Niccol\u00f2 GL, Lohr F, Iotti C, Ciammella P. Thoracic radiotherapy in extensive disease small cell lung cancer: multicenter prospective observational TRENDS study. Cancers. 2023. https:\/\/doi.org\/10.3892\/etm.2015.2526.","journal-title":"Cancers"},{"key":"2308_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.830631","volume":"13","author":"J Yin","year":"2022","unstructured":"Yin J, Wu Y, Yang X, Gan L, Xue J. Checkpoint inhibitor pneumonitis induced by anti-PD-1\/PD-L1 therapy in non-small-cell lung cancer: occurrence and mechanism. Front Immunol. 2022;13: 830631.","journal-title":"Front Immunol"},{"issue":"7","key":"2308_CR35","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3390\/cancers10070222","volume":"10","author":"V Jain","year":"2018","unstructured":"Jain V, Berman AT. Radiation pneumonitis: old problem, new tricks. Cancers. 2018;10(7):222.","journal-title":"Cancers"},{"key":"2308_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.774807","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Zhou J, Verma V, Liu X, Wu M, Yu J, Chen D. Crossed pathways for radiation-induced and immunotherapy-related lung injury. Front Immunol. 2021;12: 774807.","journal-title":"Front Immunol"},{"key":"2308_CR37","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","volume":"85","author":"DA Palma","year":"2013","unstructured":"Palma DA, Senan S, Tsujino K, Barriger RB, Rengan R, Moreno M, Bradley JD, Kim TH, Ramella S, Marks LB, De Petris L, Stitt L, Rodrigues G. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;85:444\u201350.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2308_CR38","first-page":"983","volume":"9","author":"K Tsujino","year":"2014","unstructured":"Tsujino K, Hashimoto T, Shimada T, Yoden E, Fujii O, Ota Y, Satouchi M, Negoro S, Adachi S, Soejima T. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. J Thorac Oncol Off Publ Int Assoc Stud Lung Can. 2014;9:983\u201390.","journal-title":"J Thorac Oncol Off Publ Int Assoc Stud Lung Can"},{"key":"2308_CR39","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"M Khunger","year":"2017","unstructured":"Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest. 2017;152:271\u201381.","journal-title":"Chest"},{"key":"2308_CR40","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1158\/1078-0432.CCR-16-2033","volume":"22","author":"E Castanon","year":"2016","unstructured":"Castanon E. Anti-PD1-induced pneumonitis: capturing the hidden enemy. Clin Can Res Off J Am Assoc Can Res. 2016;22:5956\u20138.","journal-title":"Clin Can Res Off J Am Assoc Can Res"},{"key":"2308_CR41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2326-6066.CIR-16-0237","volume":"5","author":"G De Velasco","year":"2017","unstructured":"De Velasco G, Je Y, Boss\u00e9 D, Awad MM, Ott PA, Moreira RB, Schutz F, Bellmunt J, Sonpavde GP, Hodi FS, Choueiri TK. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1\/PD-L1 inhibitors in cancer patients. Cancer Immunol Res. 2017;5:312\u20138.","journal-title":"Cancer Immunol Res"},{"key":"2308_CR42","doi-asserted-by":"publisher","first-page":"8518","DOI":"10.1002\/cam4.4363","volume":"10","author":"Y Chen","year":"2021","unstructured":"Chen Y, Liu X, Huang Z, Zhao K, Wang Y, Ren F, Yu J, Meng X. Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer. Cancer Med. 2021;10:8518\u201329.","journal-title":"Cancer Med"},{"key":"2308_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.radonc.2021.01.001","volume":"157","author":"F Cousin","year":"2021","unstructured":"Cousin F, Desir C, Ben Mustapha S, Mievis C, Coucke P, Hustinx R. Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer. Radiother Oncol J European Soc Therapeut Radiol Oncol. 2021;157:47\u201355.","journal-title":"Radiother Oncol J European Soc Therapeut Radiol Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02308-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-023-02308-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-023-02308-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T23:05:13Z","timestamp":1688511913000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-023-02308-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2308"],"URL":"https:\/\/doi.org\/10.1186\/s13014-023-02308-2","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"15 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Review Board of Shandong Cancer Hospital Affiliated to Shandong First Medical University and other sub-centers (No. SDTHEC 2022003004, March 2, 2022), and is in accordance with the provisions of the Declaration of Helsinki. Due to the retrospective design, no separate informed consent was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}